'
Epigral held a conference call on 10 November 2025 to discuss the results for the quarter ended September 2025 and way forward. Mr. Maulik Patel – Chairman and Managing Director, Mr. Kaushal Soparkar – Executive Director, Mr. Rakesh Agarwal – Chief Financial Officer and Mr. Milind Kotecha – Investor Relations and Strategy of the company addressed the call.
Highlights of the Concall
- The chemical industry environment remains mixed while certain segments are seeing strong growth, others are subdued, with headwinds from an early and prolonged monsoon season and persistent geopolitical uncertainty.
- Sales volumes grew modestly by around 2 % in Q2FY26 but revenues declined by around 4 % led by lower realizations in certain product categories, despite the slight uptick in volume.
- Plant utilisation in Q2 FY26 was around 78 % (versus 73 % in the previous quarter and 83 % in Q2 FY25). For H1FY26 overall utilisation was around 75 % (versus 83 %...
Pleaselogin & subscribe to view the full report.
More Reports
|
|